Kymera Therapeutics (KYMR) Could Be 17% Undervalued Following Its Earnings Preview

Event preview for Kymera Therapeutics earnings

Kymera Therapeutics (KYMR) comes into focus as Wall Street watches for the September 2026 quarter, where the business is projected to post a loss of $1.26 per share alongside sharply higher revenue.

Expectations around an Earnings ESP of 3.64% and a Zacks Rank #3, together with two earnings beats in the past four quarters, have concentrated attention on whether Kymera can again top consensus EPS estimates.

At a share price of $114.84, Kymera Therapeutics has ridden a strong run, with a 57.83% year to date share price return and an 88.73% total shareholder return over the past year. This hints that investors see momentum building as earnings expectations and revenue projections reset risk and reward perceptions.

Scan how Kymera Therapeutics compares with other fast-moving biotech opportunities by checking a curated list of 21 high quality undiscovered gems before this earnings season reshapes the field.

Kymera Therapeutics has already rewarded investors who were in early, yet the share price still trades below the average analyst target. The next step is to test whether the current tag leaves enough valuation cushion or suggests patience.

Most Popular Narrative: 17% Undervalued

Kymera Therapeutics is framed as undervalued in the most widely followed narrative, with an estimated fair value of $137.73 versus the last close at $114.84. This puts the spotlight on whether the pipeline can live up to the expectations embedded in that gap.

The anticipated Phase II and III trials for their immunology pipeline aim to deliver biologics-like efficacy in oral form, which could enhance net margins by reducing manufacturing costs associated with biologics and potentially capturing a larger market share.

The collaboration with Sanofi on the IRAK4 program, with expanded Phase II trials, positions Kymera to fast-track toward pivotal trials, potentially accelerating time-to-market and impacting future earnings positively.

See why 5 investors see Kymera Therapeutics as 17% undervalued.

Result: Fair Value of $137.73 (UNDERVALUED)

Still, Kymera Therapeutics faces real pressure if high R&D spending does not translate into successful trials or if key partners slow clinical progress.

Find out about the key risks to this Kymera Therapeutics narrative.

Next Steps

Mixed signals on Kymera Therapeutics so far, with both concern and optimism in the mix, make it worth scanning the evidence yourself quickly before views harden. To weigh that balance directly, start with the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Kymera Therapeutics?

If Kymera Therapeutics has your attention today, use that focus to refresh your broader watchlist with a few targeted sets of companies picked by clear financial traits.

Skip the noise and quickly scan 29 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying financial profile.

• Target steadier compounding by checking 5 dividend fortresses built around companies that pair higher yields with an emphasis on durability of payouts.
• Strengthen your downside protection by reviewing a list of solid balance sheet and fundamentals (24 results) that can help you avoid heavily indebted businesses when markets turn.
• Sharpen your edge before the next move by filtering for 30 resilient stocks with low risk scores where business quality and lower risk scores are front and center.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com